{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:15:59Z","timestamp":1786648559626,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000382","name":"Society for Endocrinology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000382","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Thyroid Association"},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thyroid Res"],"DOI":"10.1186\/s13044-025-00280-5","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T09:32:08Z","timestamp":1766827928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful outcome of Rituximab treatment based on lymphocyte immunophenotyping in active Thyroid Eye Disease: a case report"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9203-7507","authenticated-orcid":false,"given":"Mirco","family":"Armenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2513-3098","authenticated-orcid":false,"given":"Sara","family":"Maioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9393-9672","authenticated-orcid":false,"given":"Chiara","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6802-0126","authenticated-orcid":false,"given":"Nicola","family":"Curr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7763-4421","authenticated-orcid":false,"given":"Giorgia","family":"Moschetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-0367","authenticated-orcid":false,"given":"Mario","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2926-0722","authenticated-orcid":false,"given":"Ilaria","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"issue":"2","key":"280_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","volume":"16","author":"PN Taylor","year":"2020","unstructured":"Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, et al. New insights into the pathogenesis and nonsurgical management of graves orbitopathy. Nat Rev Endocrinol. 2020;16(2):104\u201316.","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"280_CR2","first-page":"421","volume":"63","author":"AM Ramos-Lev\u00ed","year":"2016","unstructured":"Ramos-Lev\u00ed AM, Marazuela M. Pathogenesis of thyroid autoimmune disease: the role of cellular mechanisms. Endocrinol Nutr Organo Soc Esp Endocrinol Nutr. 2016;63(8):421\u20139.","journal-title":"Endocrinol Nutr Organo Soc Esp Endocrinol Nutr"},{"issue":"4","key":"280_CR3","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European group on graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves\u2019 orbitopathy. Eur J Endocrinol. 2021;185(4):G43\u201367.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"280_CR4","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1089\/thy.2022.0251","volume":"32","author":"HB Burch","year":"2022","unstructured":"Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, et al. Management of thyroid eye disease: A consensus statement by the American thyroid association and the European thyroid association. Thyroid. 2022;32(12):1439\u201370.","journal-title":"Thyroid"},{"key":"280_CR5","doi-asserted-by":"crossref","unstructured":"Tsokos GC. B cells, be gone\u2013B-cell depletion in the treatment of rheumatoid arthritis. N Engl J Med. 2004 June;17(25):2546\u20138.","DOI":"10.1056\/NEJMp048114"},{"issue":"12","key":"280_CR6","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1089\/thy.2018.0232","volume":"28","author":"I Muller","year":"2018","unstructured":"Muller I, Willis M, Healy S, Nasser T, Loveless S, Butterworth S, et al. Longitudinal characterization of autoantibodies to the Thyrotropin receptor (TRAb) during alemtuzumab therapy: evidence that trab May precede thyroid dysfunction by many years. Thyroid. 2018;28(12):1682\u201393.","journal-title":"Thyroid"},{"issue":"2","key":"280_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi M, Vannucchi G, Curr\u00f2 N, Campi I, Covelli D, Dazzi D, et al. Efficacy of B-Cell targeted therapy with rituximab in patients with active moderate to severe graves\u2019 orbitopathy: A randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422\u201331.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"280_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432\u201341.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"280_CR9","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4161\/mabs.26008","volume":"5","author":"J Golay","year":"2013","unstructured":"Golay J, Semenzato G, Rambaldi A, Fo\u00e0 R, Gaidano G, Gamba E, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. mAbs. 2013;5(6):826\u201337.","journal-title":"mAbs"},{"issue":"6","key":"280_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/01.ftd.0000184162.60197.c1","volume":"27","author":"MB Regazzi","year":"2005","unstructured":"Regazzi MB, Iacona I, Avanzini MA, Arcaini L, Merlini G, Perfetti V, et al. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit. 2005;27(6):785\u201392.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"280_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1530\/eje.1.02119","volume":"154","author":"M Salvi","year":"2006","unstructured":"Salvi M, Vannucchi G, Campi I, Rossi S, Bonara P, Sbrozzi F, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol. 2006;154(4):511\u20137.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"280_CR12","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/art.21871","volume":"54","author":"D Paran","year":"2006","unstructured":"Paran D, Trej\u2019o L, Caspi D. Clinical images: B cell depletion in the appendix following rituximab treatment. Arthritis Rheum. 2006;54(7):2151\u20132151.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"280_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1078\/0171-2985-00200","volume":"206","author":"C Kneitz","year":"2002","unstructured":"Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology. 2002;206(5):519\u201327.","journal-title":"Immunobiology"},{"issue":"5","key":"280_CR14","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/art.22603","volume":"56","author":"JO Pers","year":"2007","unstructured":"Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sj\u00f6gren\u2019s syndrome. Arthritis Rheum. 2007;56(5):1464\u201377.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"280_CR15","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1210\/jc.2007-1238","volume":"92","author":"D El Fassi","year":"2007","unstructured":"El Fassi D, Clemmensen O, Nielsen CH, Silkiss RZ, Heged\u00fcs L. Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with graves\u2019 disease. J Clin Endocrinol Metab. 2007;92(10):3762\u20133.","journal-title":"J Clin Endocrinol Metab"},{"key":"280_CR16","doi-asserted-by":"crossref","unstructured":"Ramwadhdoebe TH, van Baarsen LGM, Boumans MJH, Bruijnen STG, Safy M, Berger FH et al. Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatol Oxf Engl. 2019 June 1;58(6):1075\u201385.","DOI":"10.1093\/rheumatology\/key428"},{"issue":"4","key":"280_CR17","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1186\/ar2798","volume":"11","author":"M Nakou","year":"2009","unstructured":"Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11(4):R131.","journal-title":"Arthritis Res Ther"},{"key":"280_CR18","doi-asserted-by":"crossref","unstructured":"Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008 July;67(7):917\u201325.","DOI":"10.1136\/ard.2007.080960"},{"key":"280_CR19","doi-asserted-by":"crossref","unstructured":"Chen J, Chen G, Sun H. Intravenous rituximab therapy for active graves\u2019 ophthalmopathy: a meta-analysis. Hormones. 2021 June;20(2):279\u201386.","DOI":"10.1007\/s42000-021-00282-6"},{"issue":"2","key":"280_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41433-018-0285-y","volume":"33","author":"M Salvi","year":"2019","unstructured":"Salvi M, Covelli D. B cells in graves\u2019 orbitopathy: more than just a source of antibodies? Eye. 2019;33(2):230\u20134.","journal-title":"Eye"},{"issue":"3","key":"280_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.clim.2005.08.006","volume":"117","author":"R Eisenberg","year":"2005","unstructured":"Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 \u2018what do B-cells do?\u2019. Clin Immunol Orlando Fla. 2005;117(3):207\u201313.","journal-title":"Clin Immunol Orlando Fla"},{"issue":"2","key":"280_CR22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/art.20858","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52(2):501\u201313.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"280_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.clim.2006.08.016","volume":"122","author":"T Vallerskog","year":"2007","unstructured":"Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol Orlando Fla. 2007;122(1):62\u201374.","journal-title":"Clin Immunol Orlando Fla"},{"issue":"11","key":"280_CR24","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00296-019-04350-4","volume":"39","author":"I Antonopoulos","year":"2019","unstructured":"Antonopoulos I, Daoussis D, Lalioti ME, Markatseli TE, Drosos AA, Taraviras S, et al. B cell depletion treatment decreases CD4\u2009+\u2009IL4\u2009+\u2009and CD4\u2009+\u2009CD40L\u2009+\u2009T cells in patients with systemic sclerosis. Rheumatol Int. 2019;39(11):1889\u201398.","journal-title":"Rheumatol Int"},{"issue":"3","key":"280_CR25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clim.2008.09.007","volume":"130","author":"D El Fassi","year":"2009","unstructured":"El Fassi D, Banga JP, Gilbert JA, Padoa C, Heged\u00fcs L, Nielsen CH. Treatment of graves\u2019 disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol Orlando Fla. 2009;130(3):252\u20138.","journal-title":"Clin Immunol Orlando Fla"},{"issue":"1","key":"280_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","volume":"117","author":"D Khanna","year":"2010","unstructured":"Khanna D, Chong KKL, Afifiyan NF, Hwang CJ, Lee DK, Garneau HC, et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology. 2010;117(1):133\u2013e1392.","journal-title":"Ophthalmology"}],"container-title":["Thyroid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-025-00280-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13044-025-00280-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-025-00280-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T09:32:10Z","timestamp":1766827930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13044-025-00280-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["280"],"URL":"https:\/\/doi.org\/10.1186\/s13044-025-00280-5","relation":{},"ISSN":["1756-6614"],"issn-type":[{"value":"1756-6614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethical committee of Milano Area 2 (permission 0004946 69_2020bis 7\/2\/2020 ID 1333).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"I.M. is an Associate Editor of the Journal and the Guest Editor of this Collection; she was not involved in handling this manuscript during the manuscript review process. She received consulting fees from Alexion Pharma, Amgen, Merck, Tourmaline, Argenx and Lundbeck. M.S. received consulting fees from IBSA, Argenx, Third Rock Ventures, Tourmaline, Immunovant, Lycia, Amgen, Viridian, Merck. M.A., S.M., C.R., G.M., N.C. have no disclosures to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}